The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes

Objective. To study the effect of liraglutide on the thickness of epicardial adipose tissue (EAT) in type 2 diabetes mellitus (T2DM) patients with abdominal obesity. Methods. Abdominal obesity T2DM patients with poor glycemic control were collected and treated with liraglutide. The changes of blood...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Na Zhao, Xiaoying Wang, Yongbo Wang, Junjie Yao, Chunhong Shi, Jianling Du, Ran Bai
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/2f54444904f94ecf8e2a1a3f259366e6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2f54444904f94ecf8e2a1a3f259366e6
record_format	dspace
spelling	oai:doaj.org-article:2f54444904f94ecf8e2a1a3f259366e62021-11-29T00:55:48ZThe Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes2314-675310.1155/2021/5578216https://doaj.org/article/2f54444904f94ecf8e2a1a3f259366e62021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/5578216https://doaj.org/toc/2314-6753Objective. To study the effect of liraglutide on the thickness of epicardial adipose tissue (EAT) in type 2 diabetes mellitus (T2DM) patients with abdominal obesity. Methods. Abdominal obesity T2DM patients with poor glycemic control were collected and treated with liraglutide. The changes of blood glucose, blood lipid, waist circumference, body mass index (BMI), and EAT thickness were compared after 3 months of treatment with liraglutide. Cardiac magnetic resonance imaging (MRI) was used to measure EAT thickness. Results. After 3 months of treatment with liraglutide, glycosylated hemoglobin (HbA1c) decreased from 9.81±1.46% to 6.94±1.29% (95%CI=2.14–3.59, p<0.001). The weight decreased from 91.67±16.29 kg to 87.29±16.43 kg (95%CI=2.97–5.79, p<0.001). Waist circumference before treatment was 103.69±9.14 cm, and after treatment was 96.42±8.42 cm (95%CI=5.04–9.50, p<0.001). Total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) were significantly lower than those before treatment. TC decreased from 5.34±1.05 mmol/L to 4.86±0.97 mmol/L (95%CI=0.15–0.82, p<0.001). TG was 1.89 (1.48-3.17) and then to 1.92±0.69 (p=0.03). LDL-C decreased from 3.39±0.84 mmol/L to 3.01±0.74 mmol/L (95%CI=0.17–0.59, p=0.001). HDL-C increased by 1.7% after treatment, with no significant difference (p=0.062). More importantly, the thickness of EAT decreased from 5.0 (5.0-7.0) mm to 3.95±1.43 mm (p<0.001) after liraglutide administered for 3 months. Conclusion. Liraglutide significantly reduces EAT thickness in T2DM with abdominal obesity, which provides theoretical support for the cardiovascular benefits of liraglutide.Na ZhaoXiaoying WangYongbo WangJunjie YaoChunhong ShiJianling DuRan BaiHindawi LimitedarticleDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENJournal of Diabetes Research, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	Diseases of the endocrine glands. Clinical endocrinology RC648-665 Na Zhao Xiaoying Wang Yongbo Wang Junjie Yao Chunhong Shi Jianling Du Ran Bai The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes
description	Objective. To study the effect of liraglutide on the thickness of epicardial adipose tissue (EAT) in type 2 diabetes mellitus (T2DM) patients with abdominal obesity. Methods. Abdominal obesity T2DM patients with poor glycemic control were collected and treated with liraglutide. The changes of blood glucose, blood lipid, waist circumference, body mass index (BMI), and EAT thickness were compared after 3 months of treatment with liraglutide. Cardiac magnetic resonance imaging (MRI) was used to measure EAT thickness. Results. After 3 months of treatment with liraglutide, glycosylated hemoglobin (HbA1c) decreased from 9.81±1.46% to 6.94±1.29% (95%CI=2.14–3.59, p<0.001). The weight decreased from 91.67±16.29 kg to 87.29±16.43 kg (95%CI=2.97–5.79, p<0.001). Waist circumference before treatment was 103.69±9.14 cm, and after treatment was 96.42±8.42 cm (95%CI=5.04–9.50, p<0.001). Total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) were significantly lower than those before treatment. TC decreased from 5.34±1.05 mmol/L to 4.86±0.97 mmol/L (95%CI=0.15–0.82, p<0.001). TG was 1.89 (1.48-3.17) and then to 1.92±0.69 (p=0.03). LDL-C decreased from 3.39±0.84 mmol/L to 3.01±0.74 mmol/L (95%CI=0.17–0.59, p=0.001). HDL-C increased by 1.7% after treatment, with no significant difference (p=0.062). More importantly, the thickness of EAT decreased from 5.0 (5.0-7.0) mm to 3.95±1.43 mm (p<0.001) after liraglutide administered for 3 months. Conclusion. Liraglutide significantly reduces EAT thickness in T2DM with abdominal obesity, which provides theoretical support for the cardiovascular benefits of liraglutide.
format	article
author	Na Zhao Xiaoying Wang Yongbo Wang Junjie Yao Chunhong Shi Jianling Du Ran Bai
author_facet	Na Zhao Xiaoying Wang Yongbo Wang Junjie Yao Chunhong Shi Jianling Du Ran Bai
author_sort	Na Zhao
title	The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes
title_short	The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes
title_full	The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes
title_fullStr	The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes
title_full_unstemmed	The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes
title_sort	effect of liraglutide on epicardial adipose tissue in type 2 diabetes
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/2f54444904f94ecf8e2a1a3f259366e6
work_keys_str_mv	AT nazhao theeffectofliraglutideonepicardialadiposetissueintype2diabetes AT xiaoyingwang theeffectofliraglutideonepicardialadiposetissueintype2diabetes AT yongbowang theeffectofliraglutideonepicardialadiposetissueintype2diabetes AT junjieyao theeffectofliraglutideonepicardialadiposetissueintype2diabetes AT chunhongshi theeffectofliraglutideonepicardialadiposetissueintype2diabetes AT jianlingdu theeffectofliraglutideonepicardialadiposetissueintype2diabetes AT ranbai theeffectofliraglutideonepicardialadiposetissueintype2diabetes AT nazhao effectofliraglutideonepicardialadiposetissueintype2diabetes AT xiaoyingwang effectofliraglutideonepicardialadiposetissueintype2diabetes AT yongbowang effectofliraglutideonepicardialadiposetissueintype2diabetes AT junjieyao effectofliraglutideonepicardialadiposetissueintype2diabetes AT chunhongshi effectofliraglutideonepicardialadiposetissueintype2diabetes AT jianlingdu effectofliraglutideonepicardialadiposetissueintype2diabetes AT ranbai effectofliraglutideonepicardialadiposetissueintype2diabetes
_version_	1718407759595044864

The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes

Ejemplares similares